FHTX
Foghorn Therapeutics Inc.
NasdaqGMUSDEQUITY
DELAYED
Last price
7.09
▲ 0.08 (1.14%)
MARKET · —
Price
Open
8.00
Prev close
7.01
Day high
7.35
Day low
6.95
Volume
528.06K
Market cap
—
P/E (TTM)
—
52W range
3.27 – 7.61
Trailing performance
Returnvs SPY
1W
+12.94%
+14.3%
1M
+39.45%
+35.7%
3M
+69.95%
+66.9%
6M
+23.39%
+12.3%
YTD
+30.93%
+18.6%
1Y
+34.41%
+14.4%
3Y
-21.44%
-95.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
6.68
+6.06% from price
SMA 20
5.86
+20.67% from price
SMA 50
5.27
+34.09% from price
SMA 100
4.89
+45.11% from price
SMA 200
5.03
+40.61% from price
EMA 12
6.49
+9.21% from price
EMA 26
5.96
+19.00% from price
EMA 50
5.50
+28.84% from price
RSI (14)
71.9
Overbought
MACD (12,26,9)
0.53
Hist 0.12
ATR (14)
0.50
7.08% of price
Realised vol 30D
77.0%
Annualised
Bollinger upper
7.68
20, 2σ
Bollinger lower
4.04
20, 2σ
50 / 200 cross
Golden
5.27 vs 5.03
Trend bias
Above 200
+40.61%
Risk profile
Beta vs SPY
1.92
More volatile than market
Correlation to SPY
0.32
Loosely linked
Realised vol 30D
77.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-46.1%
Peak to trough
Max drawdown 5Y
-87.7%
Peak to trough
ATR 14
0.50
7.08% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy
Zacks · 8d ago
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade
Zacks · 12d ago
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates
Zacks · 16d ago
Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update
GlobeNewswire · 16d ago
Acadia Healthcare (ACHC) Surpasses Q2 Earnings and Revenue Estimates
Zacks · 25d ago
Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?
Zacks · 50d ago
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
GlobeNewswire · 78d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.